Harnessing Vδ1+ T cells for next-generation immunotherapy: from mechanistic insights to clinical translation
-
By
-
Fan Wang
-
Jiaxuan Zhao
-
Tongcun Zhang
-
Jiangzhou Shi
-
June 9, 2026
-
Clinical Scorecard: Exploiting Vδ1+ T Cells for Advanced Immunotherapy: Insights into Mechanisms and Clinical Applications
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | MHC-unrestricted recognition, functional plasticity in inflammatory microenvironments |
| Target Population | |
| Care Setting | |
Key Highlights
- Vδ1+ T cells can recognize targets independently of MHC expression.
- They exhibit enhanced intratumoral infiltration and sustained functionality in immunosuppressive environments.
- Genetically engineered γδ T cells show potent anti-tumor efficacy with lower cytokine release.
Guideline-Based Recommendations
Diagnosis
Management
- Consider Vδ1+ T cell-based therapies for patients with solid tumors where supported by evidence.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with advanced tumors exhibiting MHC class I downregulation.
Vδ1+ T cells may provide therapeutic options where conventional treatments fail.
Clinical Best Practices
- Utilize Vδ1+ T cells to target tumors with MHC deficiency.
Related Resources & Content
